HDAC9 and early-onset autosomal dominant Alzheimer disease: Mounting evidence from recent studies has demonstrated the clinical efficacy of HDAC inhibitors across various neurological disorders, including Parkinson’s disease and Alzheimer’s disease, among others (Zhang et al., 2024).